Humulin M3 Kwikpen (Insulin Human (Rdna))

Humulin M3 Kwikpen is indicated for the management of hyperglycemia in adults with diabetes.

• Treatment of type 1 diabetes mellitus when rapid‑acting insulin is needed.
• Treatment of type 2 diabetes mellitus as part of a comprehensive glycemic control plan.
• Use as a mealtime (prandial) insulin to cover carbohydrate intake.
• Combination with a long‑acting basal insulin for basal‑bolus therapy.
• Suitable for patients who require multiple daily injections (MDI) for optimal control.
• Can be employed during transition from insulin pump therapy to injection therapy.

• Humulin M3 Kwikpen contains recombinant human insulin that binds to the insulin receptor on target cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake in muscle and adipose tissue, and inhibiting hepatic gluconeogenesis. The rapid‑acting formulation results in a quick onset of action after subcutaneous injection.

Adverse reactions to Humulin M3 Kwikpen are generally related to its insulin activity and injection site.

Common

• Hypoglycemia, presenting as sweating, shakiness, or confusion.
• Mild pain, redness, or swelling at the injection site.
• Lipodystrophy, including localized lipoatrophy or lipohypertrophy.
• Modest weight gain associated with improved glycemic control.
• Transient blurred vision or dizziness.
• Nausea or mild gastrointestinal discomfort.
• Localized bruising or hematoma at injection site.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Insulin‑induced edema or heart failure exacerbation in susceptible patients.
• Serum sickness‑like reaction with fever, rash, and arthralgia.

When using Humulin M3 Kwikpen, several precautions should be considered to ensure safe and effective therapy.

• Store in a refrigerator between 2 °C and 8 °C; do not freeze and discard after 28 days of in‑use.
• Rotate injection sites within the abdomen, thigh, or upper arm to reduce lipodystrophy.
• Perform frequent blood‑glucose monitoring, especially when initiating therapy or changing dose.
• Adjust insulin dose during periods of illness, increased physical activity, or emotional stress.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Pregnancy and lactation categories are not established; discuss risks and benefits with a healthcare professional.

Humulin M3 Kwikpen may interact with other medicines that affect blood glucose, insulin metabolism, or hypoglycemia awareness.

Avoid

• Simultaneous administration of other rapid‑acting insulin preparations without appropriate dose reduction.
• Beta‑adrenergic blockers that can mask signs of hypoglycemia.
• Monoamine oxidase inhibitors, which may enhance insulin’s glucose‑lowering effect.
• Thyroid hormones that may alter insulin sensitivity.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids or thiazide diuretics that raise blood glucose and may require higher insulin doses.
• Alcohol consumption, which can cause delayed hypoglycemia.
• Growth hormone therapy, which can increase insulin resistance.